Eli Lilly's Experimental Gene Therapy Lowers Cholesterol in Early-Stage Study
[출처/시간] MT Newswires - 4:27 AM ET, 05/26/2026 04:27 AM EDT, 05/26/2026 (MT Newswires) -- Eli Lilly (LLY) said Monday its experimental gene-editing therapy, VERVE-102, reduced LDL cholesterol and PCSK9 protein levels in a phase 1 study involving adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. The drug maker said a single dose of VERVE-102 produced dose-dependent reductions in PCSK9 levels ranging from
[출처/시간] MT Newswires - 4:27 AM ET, 05/26/2026
04:27 AM EDT, 05/26/2026 (MT Newswires) -- Eli Lilly (LLY) said Monday its experimental gene-editing therapy, VERVE-102, reduced LDL cholesterol and PCSK9 protein levels in a phase 1 study involving adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.
The drug maker said a single dose of VERVE-102 produced dose-dependent reductions in PCSK9 levels ranging from 51% to 88%, while LDL cholesterol fell between 9% and 62% across tested dose levels in a interim analysis.
The effects lasted up to 18 months after treatment, the company said.
Lilly said it plans to begin a phase 2 study of VERVE-102 by the end of the year.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
